Now Enrolling Patients

Get StartedAGA-0044 November 2023

Now FDA Approved

for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older1

AGAMREE® is a corticosteroid with a novel structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in DMD.1,2

View Press ReleaseSee Product Availability

Learn more about Catalyst Pathways® patient support

Visit Website

Register for updates about AGAMREE

Sign up to stay informed with important news about AGAMREE, including commercial availability.

*Required field.

If I later wish to stop receiving this information, I may click on the Unsubscribe link that appears at the bottom of all future communications. By completing this registration, I confirm that I am 18 years of age or older and a US resident.

NOTE: By providing this information, you are only requesting more information about AGAMREE and are not enrolling in Catalyst Pathways.

What is AGAMREE?

AGAMREE is a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

Important Safety Information

Patients should not take AGAMREE if they:

  • are allergic to vamorolone or any of the inactive ingredients in AGAMREE.

What is the most important information I should know about AGAMREE?

  • Do not stop AGAMREE, or change the amount taken, without first checking with your healthcare provider. There may be a need for gradual dose reductions to decrease the risk of adrenal insufficiency crisis, which can be fatal.
  • There is an increased risk of infection when taking corticosteroids like AGAMREE. Tell your healthcare provider if the patient has had recent or ongoing infections or has recently received a vaccine. Seek immediate medical advice in the case of fever or other signs of infection. Some infections can be severe, and sometimes fatal. Patients should avoid exposure to chickenpox or measles; alert your healthcare provider immediately if exposure occurs.
  • Corticosteroids, including AGAMREE, can cause an increase in blood pressure and water retention. Your healthcare provider may monitor for these increases during treatment.
  • There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like AGAMREE.
  • Corticosteroids, including AGAMREE, can cause severe behavioral and mood changes. Seek medical attention if behavioral or mood changes develop.
  • There is a risk of osteoporosis with prolonged use of corticosteroids like AGAMREE, which can lead to vertebral and long bone fractures.
  • Corticosteroids like AGAMREE may cause cataracts or glaucoma. Your healthcare provider should monitor for these conditions if AGAMREE treatment continues for more than 6 weeks.
  • Immunizations should be up to date according to immunization guidelines prior to starting therapy with AGAMREE. Live‑attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting AGAMREE. Live‑attenuated or live vaccines should not be administered in patients taking AGAMREE.
  • Rare instances of severe allergic reaction have occurred in patients receiving corticosteroid therapy.

Before taking AGAMREE, tell your healthcare provider about all medical conditions, including if the patient:

  • has decreased liver function
  • is pregnant or planning to become pregnant. AGAMREE can harm an unborn baby.
  • is breastfeeding or planning to breastfeed. AGAMREE may appear in breastmilk and could affect a nursing child.

Certain medications can cause an interaction with AGAMREE. Tell your healthcare provider about all the medicines the patient takes, including prescription and over-the-counter medicines, dietary supplements, and herbal products.

What are the possible side effects of AGAMREE? The most common side effects with AGAMREE include facial puffiness (cushingoid features), psychiatric disorders, vomiting, weight gain, and vitamin D deficiency. These are not all the possible side effects of AGAMREE.

Call your doctor for medical advice about side effects.

Please see full Prescribing Information for additional Important Safety Information.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals, Inc. at 1-844-347-3277 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is AGAMREE?

AGAMREE is a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

Important Safety Information

Patients should not take AGAMREE if they:

  • are allergic to vamorolone or any of the inactive ingredients in AGAMREE.

What is the most important information I should know about AGAMREE?

  • Do not stop AGAMREE, or change the amount taken, without first checking with your healthcare provider. There may be a need for gradual dose reductions to decrease the risk of adrenal insufficiency crisis, which can be fatal.
  • There is an increased risk of infection when taking corticosteroids like AGAMREE. Tell your healthcare provider if the patient has had recent or ongoing infections or has recently received a vaccine. Seek immediate medical advice in the case of fever or other signs of infection. Some infections can be severe, and sometimes fatal. Patients should avoid exposure to chickenpox or measles; alert your healthcare provider immediately if exposure occurs.
  • Corticosteroids, including AGAMREE, can cause an increase in blood pressure and water retention. Your healthcare provider may monitor for these increases during treatment.
  • There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like AGAMREE.
  • Corticosteroids, including AGAMREE, can cause severe behavioral and mood changes. Seek medical attention if behavioral or mood changes develop.
  • There is a risk of osteoporosis with prolonged use of corticosteroids like AGAMREE, which can lead to vertebral and long bone fractures.
  • Corticosteroids like AGAMREE may cause cataracts or glaucoma. Your healthcare provider should monitor for these conditions if AGAMREE treatment continues for more than 6 weeks.
  • Immunizations should be up to date according to immunization guidelines prior to starting therapy with AGAMREE. Live‑attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting AGAMREE. Live‑attenuated or live vaccines should not be administered in patients taking AGAMREE.
  • Rare instances of severe allergic reaction have occurred in patients receiving corticosteroid therapy.

Before taking AGAMREE, tell your healthcare provider about all medical conditions, including if the patient:

  • has decreased liver function
  • is pregnant or planning to become pregnant. AGAMREE can harm an unborn baby.
  • is breastfeeding or planning to breastfeed. AGAMREE may appear in breastmilk and could affect a nursing child.

Certain medications can cause an interaction with AGAMREE. Tell your healthcare provider about all the medicines the patient takes, including prescription and over-the-counter medicines, dietary supplements, and herbal products.

What are the possible side effects of AGAMREE? The most common side effects with AGAMREE include facial puffiness (cushingoid features), psychiatric disorders, vomiting, weight gain, and vitamin D deficiency. These are not all the possible side effects of AGAMREE.

Call your doctor for medical advice about side effects.

Please see full Prescribing Information for additional Important Safety Information.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals, Inc. at 1-844-347-3277 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References

1. AGAMREE (vamorolone) Oral Suspension [prescribing information]; 2023. 2. Liu X, Wang Y, Gutierrez JS, et al. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. 2020;117(39):24285-24293.